aspirin has been researched along with Hemorrhagic Stroke in 8 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Hemorrhagic Stroke: Stroke due to rupture of a weakened blood vessel in the brain (e.g., CEREBRAL HEMISPHERES; CEREBELLUM; SUBARACHNOID SPACE).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 8.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 7.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 4.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "To evaluate the effects of aspirin in the primary prevention, we evaluated disability grades and mortality after ischemic/hemorrhagic stroke and myocardial infarction (MI)." | 4.31 | Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study. ( Kang, MJ; Kim, HS; Kim, JH; Lee, JH; Lim, HS; Park, D; Yoon, SY, 2023) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "Aspirin and warfarin increased the risk for hemorrhagic stroke by 3." | 3.96 | Predictors of hemorrhagic stroke in older persons taking nonsteroidal anti-inflammatory drugs: Results from the Food and Drug Administration Adverse Event Reporting System. ( McDonald, DD; Srisopa, P, 2020) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 3.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Hemorrhagic stroke is the most common type of obstetric stroke." | 2.72 | Stroke in Pregnancy: A Multidisciplinary Approach. ( Camargo, EC; Singhal, AB, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 1 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 1 |
| Rabinovich, Y | 1 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Lee, YJ | 1 |
| Je, NK | 1 |
| Kim, JH | 1 |
| Park, D | 1 |
| Lim, HS | 1 |
| Kang, MJ | 1 |
| Lee, JH | 1 |
| Yoon, SY | 1 |
| Kim, HS | 1 |
| Chichareon, P | 1 |
| Modolo, R | 1 |
| Kerkmeijer, L | 1 |
| Tomaniak, M | 1 |
| Kogame, N | 1 |
| Takahashi, K | 1 |
| Chang, CC | 1 |
| Komiyama, H | 1 |
| Moccetti, T | 1 |
| Talwar, S | 1 |
| Colombo, A | 1 |
| Maillard, L | 1 |
| Barlis, P | 1 |
| Wykrzykowska, J | 1 |
| Piek, JJ | 1 |
| Garg, S | 1 |
| Hamm, C | 1 |
| Steg, PG | 1 |
| Jüni, P | 1 |
| Valgimigli, M | 1 |
| Windecker, S | 1 |
| Onuma, Y | 1 |
| Mehran, R | 1 |
| Serruys, PW | 1 |
| McDonald, DD | 1 |
| Srisopa, P | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 1 |
| Khera, A | 1 |
| Lee, HL | 1 |
| Kim, JT | 1 |
| Lee, JS | 1 |
| Park, MS | 1 |
| Choi, KH | 1 |
| Cho, KH | 1 |
| Kim, BJ | 1 |
| Park, JM | 1 |
| Kang, K | 1 |
| Lee, SJ | 1 |
| Kim, JG | 1 |
| Cha, JK | 1 |
| Kim, DH | 1 |
| Park, TH | 1 |
| Park, SS | 1 |
| Lee, KB | 1 |
| Lee, J | 2 |
| Hong, KS | 1 |
| Cho, YJ | 1 |
| Park, HK | 1 |
| Lee, BC | 1 |
| Yu, KH | 1 |
| Sun Oh, M | 1 |
| Kim, DE | 1 |
| Ryu, WS | 1 |
| Choi, JC | 1 |
| Kwon, JH | 1 |
| Kim, WJ | 1 |
| Shin, DI | 1 |
| Sohn, SI | 1 |
| Hong, JH | 1 |
| Bae, HJ | 1 |
| Camargo, EC | 1 |
| Singhal, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
2 reviews available for aspirin and Hemorrhagic Stroke
| Article | Year |
|---|---|
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
Stroke in Pregnancy: A Multidisciplinary Approach.
Topics: Aspirin; Brain Diseases; Cardiomyopathies; Cesarean Section; Eclampsia; Embolism, Paradoxical; Femal | 2021 |
1 trial available for aspirin and Hemorrhagic Stroke
| Article | Year |
|---|---|
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
5 other studies available for aspirin and Hemorrhagic Stroke
| Article | Year |
|---|---|
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |
Pre-aspirin use has no benefit on the neurological disability and mortality after cardiovascular events: A nation-wide population-based cohort study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cohort Studies; Hemorrhagic Stroke; Humans; Platelet Aggrega | 2023 |
Predictors of hemorrhagic stroke in older persons taking nonsteroidal anti-inflammatory drugs: Results from the Food and Drug Administration Adverse Event Reporting System.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Hemorrhagic Stroke; Human | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platel | 2020 |